When Triptans Are Unsafe
Do not prescribe triptans to patients with cardiovascular disease, cerebrovascular disease, peripheral vascular disease, uncontrolled hypertension, or hemiplegic/basilar migraine, and avoid them in pregnancy and lactation 1.
Absolute Cardiovascular Contraindications
Triptans cause vasoconstriction through 5-HT1B/1D receptor activation and are absolutely contraindicated in:
- Coronary artery disease (including prior MI, angina, or documented ischemia)
- Cerebrovascular disease (prior stroke, TIA, or documented cerebrovascular insufficiency)
- Peripheral vascular disease (including ischemic bowel disease)
- Uncontrolled hypertension
- Cardiac arrhythmias (particularly those with hemodynamic significance)
These contraindications exist despite limited evidence of actual cardiovascular events in clinical trials 2, 3. However, a 2022 study found that 13.9% of patients prescribed triptans had at least one contraindication, with cardiac arrhythmia (8.4%), cerebrovascular disease (3.7%), and coronary artery disease (2.6%) being most common 4. A 2025 case report documented fatal coronary vasospasm with ventricular arrhythmia storm and cardiac arrest in a 30-year-old man 90 minutes after taking 100mg sumatriptan, emphasizing that even low-risk patients can experience catastrophic outcomes 5.
Pregnancy and Lactation
The 2025 ACP guidelines explicitly state these recommendations apply to "nonpregnant and nonlactating adults" and emphasize the need to "discuss the AEs of pharmacologic treatments during pregnancy and lactation" in people of childbearing potential 1. Consider alternative therapies like CGRP antagonists or other options in these populations.
Hemiplegic and Basilar Migraine
Triptans are contraindicated in hemiplegic migraine (with motor aura) and basilar-type migraine due to theoretical risks of vasoconstriction in already compromised vascular territories 6, 3.
Medication Overuse Risk
While not an absolute contraindication, be aware that triptan use ≥10 days per month can cause medication overuse headache (MOH), compared to ≥15 days per month for NSAIDs 1. This is a lower threshold than other acute medications and requires careful monitoring.
Clinical Pitfalls to Avoid
Chest symptoms during triptan use: Most chest symptoms are nonserious and not ischemic in origin 2. However, the 2025 fatal case demonstrates that any chest pain following triptan use warrants immediate discontinuation and cardiovascular evaluation 5. Do not dismiss chest symptoms as "typical triptan side effects" without proper assessment.
Subcutaneous and intranasal routes: These formulations were more commonly prescribed among patients with contraindications compared to oral forms 4, suggesting inappropriate prescribing patterns. Route of administration does not eliminate cardiovascular risk.
Real-world adverse events: A 2024 FAERS database analysis identified reversible cerebral vasoconstriction syndrome as a significant adverse event across all triptans, along with respiratory (dyspnea for sumatriptan) and gastrointestinal disorders 7. Nervous system disorders were the primary adverse event category.
When to Screen for Cardiovascular Disease
Before prescribing triptans, assess for:
- History of cardiovascular, cerebrovascular, or peripheral vascular disease
- Uncontrolled hypertension (measure blood pressure)
- Cardiac arrhythmias
- Multiple cardiovascular risk factors (diabetes, smoking, obesity, family history, age >50 years for men, postmenopausal women)
- Pregnancy status in women of childbearing age
For patients with multiple risk factors but no established disease, consider cardiovascular evaluation before initiating triptans 6, 2.